Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Abbott Laboratories

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              INDIA India

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Abbott’s Once-A-Day Ivabradine Receives DCGI Approval for Heart Failure and Angina patients

              Contact the Supplier

              Lead Product(s): Ivabradine

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 02, 2020

              Details:

              Approval marks the first once-a-day formulation for Ivabradine in India, which will help increase adherence to therapy for chronic heart failure and chronic stable angina.

              Zydus Cadila

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              INDIA India

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Zydus Cadila Receives Final Approval from the Usfda for Cisatracurium Besylate Injection

              Contact the Supplier

              Lead Product(s): Midodrine

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 02, 2020

              Details:

              Zydus Cadila has received final approval from the USFDA to market Cisatracurium Besylate Injection USP (US RLD: Nimbex ®) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial.

              Cipla

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              INDIA India

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Cipla and Stempeutics Collaborate for Launch of Stempeucel®, First ‘Made in India’ Cell Therapy to Treat Critical Limb Ischemia (CLI)

              Contact the Supplier

              Lead Product(s): Bone marrow-derived allogeneic mesenchymal stromal cells

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Stempeucel

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Stempeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 20, 2020

              Details:

              Stempeucel® has been developed by Stempeutics and is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment. Cipla will market and distribute in Stempeucel® India.

              Stempeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              INDIA India

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Stempeutics Inks Pact with Novumcella for Development Co-Operation of Stempeucel to Treat CLI Due to Buerger’s Disease

              Contact the Supplier

              Lead Product(s): Bone marrow-derived allogeneic mesenchymal stromal cells

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Novumcella

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 28, 2020

              Details:

              As per the agreement, Novumcella will initially provide regulatory support services to Stempeutics for getting approval from PMDA, Japan for conduct of bridge study in Japan for commercializing Stempeucel® product for Buerger’s Disease.

              PharmaCompass__DigitalAd